Visualize how your peptide clears from the body — half-life, steady state, and accumulation for every injection schedule.
Half-Life
~1 min
Time for 50 % to be eliminated
Steady State
~4 min
≈ 4.3 half-lives
Accumulation
×1.00
Cmax at steady state ÷ Cmax first dose
Gone After
~7 min
after last dose
Source: Domschke et al., Gut 1978 (intravenous disappearance; n=4). Research tool. Uses a simplified first-order elimination model and normalizes concentration to % of peak. Not a medical or dosing recommendation. VIP: ~1 min.
A small human study reported an average plasma disappearance half-time of approximately one minute after an intravenous VIP infusion was stopped.
This rapid value is specific to the intravenous route, four volunteers, and the study's sampling design. It is not a universal half-life or a statement about vial stability.
Domschke et al., Gut 1978: approximately one-minute intravenous disappearance half-time.
Vasoactive intestinal peptide, commonly abbreviated VIP, is an endogenous signaling peptide composed of 28 amino acids and completed by a C-terminal amide. Sequence work established the compact peptide architecture that is now used as the reference identity for VIP research. Although its historical name points to one tissue context, VIP is studied more broadly as a member of the secretin-family signaling system. Its scientific identity should therefore be understood at the molecular and receptor level, not as a promise of a particular biological outcome.
This product contains 10 mg of lyophilized VIP in a research vial. The mass on the label describes the supplied research material; it is not a dosage recommendation. The format is intended for controlled laboratory workflows in which investigators define their own validated analytical or experimental protocol. It is not presented as a pharmaceutical preparation, a clinical substitute or a material suitable for administration to people or animals.
For laboratory research use only. Not for human or veterinary use, diagnosis, treatment, prevention or consumption. No clinical equivalence, suitability for administration or therapeutic performance is represented.